Top-Down vs Step-Up Therapy for Crohn's: PROFILE Trial

If you have recently been diagnosed with Crohn's disease, one of the first big decisions you and your gastroenterologist will face is how aggressively to treat it from the start. For decades, the standard answer was to begin with milder drugs and escalate only when they failed. But the PROFILE trial, published in The Lancet Gastroenterology and Hepatology in February 2024, has produced some of the strongest evidence yet that top-down therapy for Crohn's disease - starting with a biologic right away - leads to dramatically better outcomes than the traditional step-up approach. Combined with major guideline shifts from the ACG and AGA in 2025, the treatment landscape for newly diagnosed patients is changing fast.

Key Takeaways

• In the PROFILE trial, 79% of patients on top-down therapy achieved sustained steroid-free remission at one year, compared with just 15% on step-up (1)
• Top-down patients had a ten-fold lower rate of urgent abdominal surgery: 0.5% versus 5% (2, 3)
• Endoscopic remission (no visible ulcers) was reached by 67% of top-down patients, far above the 20-30% typical in clinical trials (2)
• The top-down arm actually had fewer total adverse events and fewer serious adverse events than step-up (1)
• Both the 2025 ACG and AGA guidelines now recommend early advanced therapy over traditional step-up for moderate-to-severe Crohn's (5, 6)
• Top-down is becoming the default, but shared decision-making with your gastroenterologist remains essential

What Top-Down and Step-Up Therapy Mean in Crohn's Disease

Understanding the difference between these two strategies is the foundation for any treatment conversation. The names describe the order in which medications are introduced, and that order turns out to matter far more than many of us realized.

The Traditional Step-Up Approach

For most of the history of Crohn's treatment, the standard practice was to start with the gentlest tools available and move up only when each one failed. A newly diagnosed patient might begin with corticosteroids to control the immediate flare, then transition to an immunomodulator such as azathioprine or methotrexate for maintenance. Only after those options proved inadequate - sometimes after months or years of incomplete control - would a biologic therapy like infliximab (an anti-TNF agent) be considered. The logic was straightforward: why expose someone to a potent drug with potential side effects if a milder one might do the job? As we explored in our overview of biological treatments for Crohn's disease past and present, biologics were once seen as a last resort rather than a starting point.

What Top-Down Therapy Looks Like

Top-down therapy flips the sequence. Instead of waiting for disease to prove it is aggressive enough to "earn" a biologic, treatment starts with a biologic - typically infliximab in combination with an immunomodulator - right from diagnosis. The idea is to hit the disease hard before it has a chance to cause irreversible structural damage to the bowel. Infliximab, an anti-TNF therapy, works by neutralizing a key inflammatory signal before chronic inflammation can lead to strictures, fistulas, and surgical complications.

Why the Order of Treatment Matters

The concept behind early intervention is sometimes called the "window of opportunity." In the first months after diagnosis, Crohn's disease is often primarily inflammatory. Over time, untreated or under-treated inflammation can cause fibrosis (scarring), stricturing (narrowing of the bowel), and penetrating complications that medications cannot reverse. Once structural damage is established, even the best biologic may not undo it. Top-down therapy aims to intervene during that early window, before inflammation transitions into permanent damage.

Inside the PROFILE Trial: A Landmark Study Changing Practice

The PROFILE trial is not the first study to compare these strategies, but it is the largest and most rigorously designed randomized controlled trial to do so in newly diagnosed patients, and its results have been difficult to ignore.

Study Design and Patients

PROFILE enrolled 386 newly diagnosed adult Crohn's disease patients across 40 hospitals in the United Kingdom between 2017 and 2022 (1, 2). This was a multicentre, open-label, randomized controlled trial - meaning both patients and doctors knew which treatment arm they were in, but assignment was random. Crucially, the study focused exclusively on patients who were newly diagnosed, making its findings directly relevant to the treatment decisions that happen in the first weeks after a Crohn's diagnosis.

What Was Compared

Patients were randomized to one of two strategies. The top-down arm received infliximab combined with an immunomodulator from the point of diagnosis. The accelerated step-up arm followed a more traditional pathway: corticosteroids first, then immunomodulators, with biologic therapy added only if the earlier treatments failed to achieve adequate control. The primary outcome was sustained steroid-free and surgery-free remission through week 48 - a high bar that captures what patients actually want, which is feeling well without needing steroids or an operation for an entire year (1).

The Biomarker That Did Not Pan Out

PROFILE had a secondary aim: testing whether a blood-based T-cell biomarker called PredictSURE-IBD could identify which patients would fare better on which strategy. The hope was that a simple blood test could tell clinicians which patients truly needed aggressive early therapy and which could safely start conservative. Unfortunately, the biomarker showed no clinical utility for stratifying treatment response (1, 4). The trial's treatment findings were so strong, however, that the biomarker result has become a footnote rather than the headline.

The Results: How Much Better Was Top-Down Therapy?

The numbers from PROFILE are striking, and they go well beyond a modest statistical edge. The gap between the two strategies was larger than most gastroenterologists expected.

Sustained Remission Rates

The headline finding: 79% of patients in the top-down arm achieved sustained steroid-free and surgery-free remission at 48 weeks, compared with just 15% of patients in the accelerated step-up arm (1). That is not a subtle difference. In practical terms, roughly four out of five newly diagnosed patients who started a biologic right away stayed in remission for a full year without needing steroids or surgery, versus fewer than one in six who followed the traditional escalation path.

Endoscopic Healing and Surgery Reduction

Beyond how patients felt, the trial measured what was happening inside the bowel. 67% of top-down patients achieved endoscopic remission - meaning no visible ulcers on colonoscopy - which is well above the 20-30% endoscopic remission rates typically seen in Crohn's clinical trials (2). Perhaps most compellingly for anyone facing a new diagnosis, only 0.5% of top-down patients required urgent abdominal surgery, compared with 5% in the step-up arm - a ten-fold reduction (2, 3).

Quality of Life, Steroid Use, and Hospitalizations

The benefits extended to daily life. Top-down patients reported higher quality-of-life scores, spent far less time on corticosteroids (which carry their own burden of side effects, as we discussed in our piece on long-term effects of steroid use in Crohn's disease), and had fewer hospitalizations. Counterintuitively, the top-down arm also had fewer total adverse events (168 versus 315) and fewer serious adverse events (15 versus 42) than the step-up arm (1). Starting with a more potent therapy did not mean more complications - it meant fewer.

How 2025 Treatment Guidelines Are Catching Up

Large trials take time to influence official recommendations, but the PROFILE results have landed at exactly the right moment. Two major North American guidelines updated in 2025 now reflect a clear shift toward early advanced therapy.

The Updated ACG Guideline

The 2025 American College of Gastroenterology clinical guideline now explicitly suggests against requiring patients with moderate-to-severe Crohn's disease to fail conventional therapies like thiopurines or methotrexate before starting advanced therapy (5). This is a significant departure from prior guidance that treated biologics as an escalation option rather than a first-line consideration. The guideline also recommends limiting systemic corticosteroid use to less than three months with structured tapering, and it formally discourages mesalamine for luminal Crohn's disease induction and maintenance (5).

The AGA Living Guideline

The November 2025 American Gastroenterological Association living guideline goes further, emphasizing early use of high-efficacy agents over traditional step-up approaches that rely on corticosteroids or immunomodulators as the first line (6). The AGA framework now lists several first-line options for treatment-naive patients with moderate-to-severe disease, including infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, and upadacitinib (6).

What Got Downgraded and What Got Elevated

The combined effect of these guideline changes is a clear demotion for the traditional step-up playbook. Mesalamine, long prescribed out of habit despite thin evidence in Crohn's, has been formally discouraged. Corticosteroids have been recast as short-term bridge therapy rather than a foundation. And the old requirement to "fail" a conventional drug before accessing a biologic is being dismantled. For newly diagnosed patients, this means the conversation with your gastroenterologist in 2026 should look quite different from the one a patient had in 2020.

What This Means for You as a Patient

Evidence and guidelines matter, but what ultimately matters is how they translate into your care. If you are newly diagnosed, or if you are being reconsidered for treatment escalation, here is how to use this information.

Questions to Ask Your Gastroenterologist

Come to your appointment prepared. Ask whether your disease severity, location, and risk profile fit the candidate group studied in PROFILE. Ask specifically whether top-down therapy is an option for you, and if not, why not. Bring up the 2025 guideline changes. For anyone just beginning to navigate a diagnosis, our guide to understanding life with Crohn's disease can help frame the broader picture of what to expect.

Questions worth raising include:

• "Based on my disease location and severity, would you recommend starting with a biologic?"
• "What are the risks and benefits of combination therapy (biologic plus immunomodulator) versus biologic alone?"
• "If we start with a conventional approach, what specific criteria would trigger escalation, and how quickly?"
• "How will we monitor whether treatment is working - symptoms alone, or also endoscopy and lab markers?"

Insurance, Access, and Cost Considerations

One reason step-up persisted for so long was not only clinical caution but also payer requirements. Many insurance plans historically demanded documented failure of cheaper drugs before approving biologics. As guidelines shift, these policies are evolving too, though not always at the same pace. If an insurer denies coverage for early biologic therapy, the updated ACG and AGA guidelines provide strong grounds for an appeal. Healthcare systems outside North America vary widely in how they fund advanced therapies, so patients in other countries should ask their specialists about local access pathways.

Who Might Still Reasonably Choose Step-Up

Top-down is becoming the default recommendation for moderate-to-severe Crohn's, but it is not the only reasonable choice for every patient. People with very mild, limited disease - for example, a short segment of ileal inflammation with minimal symptoms and low inflammatory markers - may still do well with conservative management under close monitoring. The key is that this should be a deliberate, informed decision made together with your care team, not a default driven by outdated habit or insurance friction.

Concerns, Caveats, and What We Still Do Not Know

No trial answers every question, and PROFILE is no exception. Being honest about the limitations is part of using the data well.

Long-Term Safety of Early Combination Therapy

PROFILE followed patients for 48 weeks, and during that period, the top-down arm actually had fewer serious adverse events and no difference in serious infection rates compared with step-up (1). This is reassuring, but one year is not a lifetime. Combination therapy with a biologic and an immunomodulator does carry an increased risk of certain infections and, in rare cases, lymphoma over longer time horizons. Ongoing monitoring and regular check-ins with your gastroenterologist remain important regardless of which strategy you and your team choose.

When Top-Down May Not Be the Right Fit

Primary non-response to infliximab - meaning the drug simply does not work for a given patient - still affects an estimated 29-41% of people with luminal Crohn's disease. Starting with a biologic does not guarantee it will work. Some patients have naturally mild disease trajectories and may never need advanced therapy at all. Others may have contraindications to specific biologics or immunomodulators. These are the kinds of individual factors that make shared decision-making, rather than a blanket protocol, the right approach.

The Future of Personalized IBD Care

The failure of the PredictSURE-IBD biomarker in PROFILE was disappointing, but it has not stopped the search for better tools. Researchers across multiple centres are working on blood-based, stool-based, and genetic markers that might eventually tell clinicians which newly diagnosed patients are headed for aggressive disease and which will have a milder course. Until those tools are validated, the pragmatic approach is to lean toward early advanced therapy for anyone with moderate-to-severe features, while keeping the door open for de-escalation if deep remission is achieved and sustained.

Frequently Asked Questions

What is top-down therapy for Crohn's disease?

Top-down therapy means starting treatment with a biologic medication - typically infliximab combined with an immunomodulator - right from diagnosis, rather than waiting for milder drugs to fail first. The PROFILE trial showed that this approach led to 79% sustained remission at one year versus 15% with step-up (1).

Is top-down therapy safe for newly diagnosed patients?

In the PROFILE trial, the top-down arm had fewer total adverse events (168 vs 315) and fewer serious adverse events (15 vs 42) compared with step-up over 48 weeks (1). No difference in serious infection rates was observed. Longer-term safety data beyond one year are still being gathered.

Does top-down therapy reduce the need for surgery?

Yes. In the PROFILE trial, only 0.5% of top-down patients required urgent abdominal surgery, compared with 5% of step-up patients - a ten-fold reduction (2, 3). This is one of the most clinically meaningful findings of the study.

Will my insurance cover early biologic therapy?

Coverage varies by country and insurer. In North America, many payers are updating policies to reflect the 2025 ACG and AGA guidelines, which now support early advanced therapy without requiring failure of conventional drugs first (5, 6). If denied, the updated guidelines can support an appeal.

Can I still choose step-up therapy?

Yes. While top-down is becoming the recommended default for moderate-to-severe Crohn's, patients with very mild or limited disease may reasonably choose a conservative approach with close monitoring. The decision should be made collaboratively with your gastroenterologist based on your specific disease profile.

What if the biologic does not work for me?

Primary non-response to infliximab occurs in an estimated 29-41% of luminal Crohn's patients. If a first biologic does not produce an adequate response, the 2025 AGA guideline lists several alternative first-line agents including adalimumab, ustekinumab, risankizumab, and others (6). Your care team can pivot to a different mechanism of action.

What questions should I ask my doctor about top-down therapy?

Ask whether your disease severity and location match the PROFILE candidate profile, what the specific risks and benefits of combination therapy are for you, how treatment response will be monitored (symptoms, endoscopy, lab markers), and what the plan is if the first biologic does not work. Bring the PROFILE trial data and the 2025 guideline updates to your appointment.

References

1. Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2024. View on PubMed
2. University of Cambridge. Improving outcomes for Crohn's patients. 2024. Read article
3. ScienceDaily. Treating newly-diagnosed Crohn's patients with advanced therapy leads to dramatic improvements in outcomes. 2024. Read article
4. European Medical Journal. PROFILE Trial: Top-Down Outperforms Step-Up Treatment for Crohn's Disease. 2024. Read article
5. American College of Gastroenterology. Updated 2025 ACG clinical guideline for the management of Crohn's disease. EBGI, 2025. Read guideline
6. American Gastroenterological Association. New AGA guideline streamlines Crohn's disease treatment. 2025. Read article